Clinical Trial Update: Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sirolimus (Rapamune) for relapse prevention in people with severe aplastic anemia who previously responded to immunosuppressive therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Sirolimus (Rapamune) (Sirolimus)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Severe Aplastic Anemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING